RLMD Earnings & Financial Statements
Relmada Therapeutics, Inc.
$3.20
-$0.04(-1.23%)
41
Overall
60
Value
45
Tech
18
Quality
Market Cap
$345.61M
Volume
908.69K
52W Range
$1.80 - $8.00
Target Price
$10.75
RLMD earnings and financial statements: Relmada Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RLMD Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$59.10M | -$83.89M | -$103.70M | -$161.25M | -$125.70M |
| EBITDA | -$57.39M | -$79.98M | -$98.79M | -$161.25M | -$125.70M |
| Net income | -$57.39M | -$79.98M | -$98.79M | -$157.04M | -$125.75M |
| EPS (diluted) | $-1.45 | $-2.65 | $-3.28 | $-5.30 | $-7.16 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $94.00M | $45.82M | $97.55M | $152.91M | $223.33M |
| Total liabilities | $7.49M | $10.30M | $12.19M | $12.47M | $15.06M |
| Shareholders’ equity | $86.51M | $35.52M | $85.36M | $140.44M | $208.26M |
| Cash and equivalents | $3.50M | $3.86M | $4.09M | $5.40M | $44.44M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$45.79M | -$51.76M | -$51.66M | -$103.80M | -$91.87M |
| Free cash flow | -$45.79M | -$51.76M | -$51.66M | -$103.80M | -$91.87M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RLMD | $3.20 | -1.2% | 908.69K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Relmada Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW